Among patients with idiopathic pulmonary fibrosis, the risk for all-cause mortality was significantly lower with vs. without angiotensin-converting enzyme inhibitor use started within 5 years before ...
A major trial finds the beta blocker bisoprolol neither improves nor worsens outcomes in people with COPD, despite the cardiovascular risk.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results